<code id='106C373D86'></code><style id='106C373D86'></style>
    • <acronym id='106C373D86'></acronym>
      <center id='106C373D86'><center id='106C373D86'><tfoot id='106C373D86'></tfoot></center><abbr id='106C373D86'><dir id='106C373D86'><tfoot id='106C373D86'></tfoot><noframes id='106C373D86'>

    • <optgroup id='106C373D86'><strike id='106C373D86'><sup id='106C373D86'></sup></strike><code id='106C373D86'></code></optgroup>
        1. <b id='106C373D86'><label id='106C373D86'><select id='106C373D86'><dt id='106C373D86'><span id='106C373D86'></span></dt></select></label></b><u id='106C373D86'></u>
          <i id='106C373D86'><strike id='106C373D86'><tt id='106C373D86'><pre id='106C373D86'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:comprehensive    Page View:71
          Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT
          Darron Cummings/AP

          Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

          The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

          advertisement

          “The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Medicare proposal to cover medical devices draws a mixed reaction
          Medicare proposal to cover medical devices draws a mixed reaction

          AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

          read more
          Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health
          Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

          John-ArneRøttingenistheheadoftheWellcomeTrust,oneoftheworld’stopprivatefundersofbiomedicalresearch.I

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          Elon Musk announces 'temporary limits' for reading Twitter posts

          0:53TheTwitterlogoisseenonaphoneinthisphotoillustrationinWashington,D.C.AlastairPike/AFPviaGettyImag